Eisai, Biogen's injectable Leqembi delayed as FDA asks for more data
Fierce Pharma
APRIL 1, 2024
What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA. What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA.
254 
Let's personalize your content